Loss Per Share (Tables)

9 Months Ended

Jul. 31, 2020

Calculation of Basic and Diluted Loss Per Share

The calculation of basic and diluted loss per share was as follows:

	Three Months Ended July 31,						Nine Months Ended July 31,
	2020			2019			2020			2019
Numerator
Net loss	$	(15,331	)	$	(5,311	)	$	(70,251	)	$	(42,389	)
Series A warrant exchange		—			—			—			(3,169	)
Series B preferred stock dividends		(800	)		(810	)		(2,531	)		(2,410	)
Series C preferred stock deemed contributions (dividends) and redemption value adjustment, net		—			884			—			(6,522	)
Series D Preferred stock deemed dividends and redemption accretion		—			(3,091	)		—			(9,752	)
Net loss attributable to common stockholders	$	(16,131	)	$	(8,328	)	$	(72,782	)	$	(64,242	)
Denominator
Weighted average basic common shares		217,966,402			45,069,911			210,389,907			21,608,427
Effect of dilutive securities ⁽¹⁾		—			—			—			—
Weighted average diluted common shares		217,966,402			45,069,911			210,389,907			21,608,427
Basic loss per share	$	(0.07	)	$	(0.18	)	$	(0.35	)	$	(2.97	)
Diluted loss per share ⁽¹⁾	$	(0.07	)	$	(0.18	)	$	(0.35	)	$	(2.97	)

(1)

Due to the net loss to common stockholders in each of the periods presented above, diluted loss per share was computed without consideration to potentially dilutive instruments as their inclusion would have been anti-dilutive. As of July 31, 2020 and 2019, potentially dilutive securities excluded from the diluted loss per share calculation are as follows:

Schedule of Potentially Dilutive Securities Excluded from the Diluted Loss Per Share Calculation

As of July 31, 2020 and 2019, potentially dilutive securities excluded from the diluted loss per share calculation are as follows:

	July 31,		July 31,
	2020		2019
Orion Warrants		8,000,000		—
May 2017 Offering - Series C Warrants		964,114		964,114
Outstanding options to purchase common stock		23,891		24,927
Unvested Restricted Stock Awards		701		28,549
Unvested Restricted Stock Units ⁽¹⁾		1,197,889		168,553
Series D Preferred Shares to satisfy conversion requirements ⁽²⁾		—		1,509
5% Series B Cumulative Convertible Preferred Stock		37,837		37,837
Series 1 Preferred Shares to satisfy conversion requirements		—		1,264
Total potentially dilutive securities		10,224,432		1,226,753

(1)

The increase in Unvested Restricted Stock Units includes 1,000,000 restricted stock units (the maximum number of restricted stock units that may be earned) reserved for issuance pursuant to a sign-on award granted to the Company’s President and Chief Executive Officer (the “CEO”) pursuant to the August 26, 2019 employment agreement between the Company and the CEO. Pursuant to the terms of such sign-on award, 500,000 restricted stock units vest on August 26, 2022 and the remaining 500,000 restricted stock units, if earned, will vest on August 26, 2022 and the number earned, if any, will be based on the weighted average price of the Company’s common stock during the thirty (30) day calendar period ending on the vesting date compared to pre-established price goals. The vesting of all restricted stock units is subject to the individual’s continuous employment with the Company through the vesting date.

(2)	The number of shares of common stock issuable upon conversion of the Series D Convertible Preferred Stock was calculated using the liquidation preference value outstanding on July 31, 2019 of $18.5 million divided by the conversion price of $16.56 per share.